|
1
|
Shimada M, Itamochi H and Kigawa J:
Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer
Manag Res. 5:67–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inuyama Y, Miyake H, Horiuchi M, Hayasaki
K, Komiyama S and Ota K: An early phase II clinical study of
cis-diammine glycolato platinum, 254-S, for head and neck cancers.
Gan To Kagaku Ryoho. 19:863–869. 1992.(In Japanese). PubMed/NCBI
|
|
3
|
Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y,
Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, et
al: A phase II clinical study of cis-diammine glycolato platinum,
254-S, for primary lung cancer. Gan To Kagaku Ryoho. 19:879–884.
1992.(In Japanese). PubMed/NCBI
|
|
4
|
He YF, Ji CS, Hu B, Fan PS, Hu CL, Jiang
FS, Chen J, Zhu L, Yao YW and Wang W: A phase II study of
paclitaxel and nedaplatin as front-line chemotherapy in Chinese
patients with metastatic esophageal squamous cell carcinoma. World
J Gastroenterol. 19:5910–5916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jung Y and Lippard SJ: Direct cellular
responses to platinum-induced DNA damage. Chem Rev. 107:1387–1407.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamashita H, Nakagawa K, Tago M, Igaki H,
Nakamura N, Shiraishi K, Sasano N and Ohtomo K: Radiation therapy
combined with cis-diammine-glycolatoplatinum (nedaplatin) and
5-fluorouracil for Japanese stage II–IV esophageal cancer compared
with cisplatin plus 5-fluorouracil regimen: A retrospective study.
Dis Esophagus. 19:15–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshioka T, Sakayori M, Kato S, Chiba N,
Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y,
et al: Dose escalation study of docetaxel and nedaplatin in
patients with relapsed or refractory squamous cell carcinoma of the
esophagus pretreated using cisplatin, 5-fluorouracil, and
radiation. Int J Clin Oncol. 11:454–460. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takigawa N, Segawa Y, Ueoka H, Kiura K,
Tabata M, Shibayama T, Takata I, Miyamoto H, Eguchi K and Harada M:
Combination of nedaplatin and vindesine for treatment of relapsed
or refractory non-small-cell lung cancer. Cancer Chemother
Pharmacol. 46:272–278. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou P, Qian L, Kozopas KM and Craig RW:
Mcl-1, a Bcl-2 family member, delays the death of hematopoietic
cells under a variety of apoptosis-inducing conditions. Blood.
89:630–643. 1997.PubMed/NCBI
|
|
10
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Belmar J and Fesik SW: Small molecule
Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther.
145:76–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang C, Shi J, Mao SY, Xu YS, Zhang D,
Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, et al: Role of p38 MAPK
in enhanced human cancer cells killing by the combination of
aspirin and ABT-737. J Cell Mol Med. 19:408–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yecies D, Carlson NE, Deng J and Letai A:
Acquired resistance to ABT-737 in lymphoma cells that up-regulate
MCL-1 and BFL-1. Blood. 115:3304–3313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Konopleva M, Contractor R, Tsao T, Samudio
I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al:
Mechanisms of apoptosis sensitivity and resistance to the BH3
mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maurer U, Charvet C, Wagman AS, Dejardin E
and Green DR: Glycogen synthase kinase-3 regulates mitochondrial
outer membrane permeabilization and apoptosis by destabilization of
MCL-1. Mol Cell. 21:749–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H,
Dong XW, Hu YZ, Lin NM, He QJ and Yang B: Synergistic antitumor
activity of gemcitabine and ABT-737 in vitro and in vivo through
disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther.
10:1264–1275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yonezawa A and Inui K: Organic cation
transporter OCT/SLC22A and H(+)/organic cation antiporter
MATE/SLC47A are key molecules for nephrotoxicity of platinum
agents. Biochem Pharmacol. 81:563–568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giaccone G: Clinical perspectives on
platinum resistance. Drugs. 59(Suppl 4): S9–S17, S37-S88. 2000.
View Article : Google Scholar
|
|
20
|
Piccart MJ, Lamb H and Vermorken JB:
Current and future potential roles of the platinum drugs in the
treatment of ovarian cancer. Ann Oncol. 12:1195–1203. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuwahara A, Yamamori M, Nishiguchi K,
Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y,
Nakamura T, et al: Replacement of cisplatin with nedaplatin in a
definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in
Japanese patients with esophageal squamous cell carcinoma. Int J
Med Sci. 6:305–311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boulikas T and Vougiouka M: Recent
clinical trials using cisplatin, carboplatin and their combination
chemotherapy drugs (review). Oncol Rep. 11:559–595. 2004.PubMed/NCBI
|
|
23
|
Simonin K, N'Diaye M, Lheureux S,
Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E,
Blanc-Fournier C and Poulain L: Platinum compounds sensitize
ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa
axis. Apoptosis. 18:492–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lakhani SA, Masud A, Kuida K, Porter GA
Jr, Booth CJ, Mehal WZ, Inayat I and Flavell RA: Caspases 3 and 7:
Key mediators of mitochondrial events of apoptosis. Science.
311:847–851. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martins LM: The serine protease Omi/HtrA2:
A second mammalian protein with a Reaper-like function. Cell Death
Differ. 9:699–701. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri
W, Krishnegowda G, Awwad A, Dewey A, Liu X, et al: Discovery of
marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that
overcomes ABT-737 resistance by binding to and targeting Mcl-1 for
proteasomal degradation. J Biol Chem. 287:10224–10235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang S and Sinicrope FA: BH3 mimetic
ABT-737 potentiates TRAIL-mediated apoptotic signaling by
unsequestering Bim and Bak in human pancreatic cancer cells. Cancer
Res. 68:2944–2951. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang C, Kaushal V, Shah SV and Kaushal GP:
Mcl-1 is downregulated in cisplatin-induced apoptosis and
proteasome inhibitors restore Mcl-1 and promote survival in renal
tubular epithelial cells. Am J Physiol Renal Physiol.
292:F1710–F1717. 2007. View Article : Google Scholar : PubMed/NCBI
|
